For help on how to get the results you want, see our search tips.
1204 results
Categories
Human Remove Human filter
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Paediatric investigation plans Remove Paediatric investigation plans filter
Authorisation status
Authorised Remove Authorised filter
-
List item
Human medicine European public assessment report (EPAR): Braftovi (updated)
Encorafenib, Melanoma, Colorectal Neoplasms
Date of authorisation: 19/09/2018,
, Revision: 5, Authorised, Last updated: 01/03/2021
-
List item
Human medicine European public assessment report (EPAR): Gencebok (updated)
Caffeine citrate, Apnea
Date of authorisation: 19/08/2020, Revision: 2, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Aubagio (updated)
Teriflunomide, Multiple Sclerosis
Date of authorisation: 26/08/2013, Revision: 17, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Eylea (updated)
aflibercept, Wet Macular Degeneration, Macular Edema, Diabetes Complications
Date of authorisation: 21/11/2012, Revision: 20, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Ondexxya (updated)
andexanet alfa, Drug-Related Side Effects and Adverse Reactions
Date of authorisation: 26/04/2019,, 
, Revision: 8, Authorised, Last updated: 01/03/2021
-
List item
Human medicine European public assessment report (EPAR): Karvea (updated)
irbesartan, Hypertension
Date of authorisation: 26/08/1997, Revision: 40, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Glivec (updated)
imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Gastrointestinal Stromal Tumors, Dermatofibrosarcoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hypereosinophilic Syndrome
Date of authorisation: 07/11/2001,, Revision: 40, Authorised, Last updated: 01/03/2021
-
List item
Human medicine European public assessment report (EPAR): CoAprovel (updated)
irbesartan, hydrochlorothiazide, Hypertension
Date of authorisation: 14/10/1998, Revision: 41, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Byetta (updated)
exenatide, Diabetes Mellitus, Type 2
Date of authorisation: 20/11/2006, Revision: 24, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Praluent (updated)
Alirocumab, Dyslipidemias
Date of authorisation: 23/09/2015, Revision: 16, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Bydureon (updated)
exenatide, Diabetes Mellitus, Type 2
Date of authorisation: 17/06/2011, Revision: 21, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Aprovel (updated)
irbesartan, Hypertension
Date of authorisation: 26/08/1997, Revision: 42, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Tadalafil Lilly (updated)
tadalafil, Erectile Dysfunction
Date of authorisation: 22/03/2017, Revision: 3, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Velmetia (updated)
sitagliptin, metformin hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 16/07/2008, Revision: 29, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Triumeq (updated)
dolutegravir sodium, lamivudine, abacavir (as sulfate), HIV Infections
Date of authorisation: 31/08/2014, Revision: 20, Authorised, Last updated: 26/02/2021 -
List item
Human medicine European public assessment report (EPAR): Trimbow (updated)
Beclometasone dipropionate, formoterol fumarate dihydrate, glycopyrronium bromide, Pulmonary Disease, Chronic Obstructive
Date of authorisation: 17/07/2017, Revision: 4, Authorised, Last updated: 26/02/2021 -
List item
Human medicine European public assessment report (EPAR): Pioglitazone Accord (updated)
pioglitazone hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 21/03/2012,
, Revision: 6, Authorised, Last updated: 26/02/2021
-
List item
Human medicine European public assessment report (EPAR): Ilumetri (updated)
tildrakizumab, Psoriasis
Date of authorisation: 17/09/2018,, Revision: 3, Authorised, Last updated: 26/02/2021
-
List item
Human medicine European public assessment report (EPAR): Actos (updated)
pioglitazone hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 13/10/2000, Revision: 26, Authorised, Last updated: 26/02/2021 -
List item
Human medicine European public assessment report (EPAR): Imbruvica (updated)
Ibrutinib, Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 21/10/2014,
, Revision: 21, Authorised, Last updated: 26/02/2021
-
List item
Human medicine European public assessment report (EPAR): Somavert (updated)
Pegvisomant, Acromegaly
Date of authorisation: 12/11/2002, Revision: 25, Authorised, Last updated: 26/02/2021 -
List item
Human medicine European public assessment report (EPAR): Vpriv (updated)
velaglucerase alfa, Gaucher Disease
Date of authorisation: 26/08/2010,
, , Revision: 14, Authorised, Last updated: 26/02/2021
-
List item
Human medicine European public assessment report (EPAR): Elonva (updated)
corifollitropin alfa, Reproductive Techniques, Assisted, Ovulation Induction
Date of authorisation: 25/01/2010, Revision: 17, Authorised, Last updated: 26/02/2021 -
List item
Human medicine European public assessment report (EPAR): Noxafil (updated)
posaconazole, Candidiasis, Mycoses, Coccidioidomycosis, Aspergillosis
Date of authorisation: 25/10/2005, Revision: 28, Authorised, Last updated: 26/02/2021 -
List item
Human medicine European public assessment report (EPAR): Nyxoid (updated)
Naloxone hydrochloride dihydrate, Opioid-Related Disorders
Date of authorisation: 09/11/2017, Revision: 5, Authorised, Last updated: 26/02/2021